Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | NSCLC | Research

Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis

Authors: Jiaqi Liu, Yan Sun, Wenjing Chen, Lingling Deng, Mengmeng Chen, Jingcheng Dong

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

Astragaloside III (AS III), a saponin-like metabolite derived from the traditional Chinese medicine Astragali Radix, has been shown to be effective in the treatment of cancer and heart failure, and a variety of digestive disorders. However, its molecular mechanism in the treatment of non-small cell lung cancer (NSCLC) is unknown.

Methods

Human lung cancer A549 cells and NCI-H460 cells and a normal human lung epithelial cell BEAS-2B were treated with different concentrations of AS III. CCK-8 and EdU staining were used to determine the anti-proliferative effects of AS III in vitro. Quantitative proteomic analysis was performed on A549 cells treated with the indicated concentrations of AS III, and the expression levels of apoptosis-related proteins were examined by Western blotting.

Results

AS III treatment significantly inhibited proliferation and increased apoptosis in A549 and H460 cells and modulated functional signaling pathways associated with apoptosis and metabolism. At the molecular level, AS III promoted a reduction in the expression of ANXA1 (p < 0.01), with increased levels of cleaved Caspase 3 and PARP 1. In addition, AS III treatment significantly decreased the LC3-I/LC3-II ratio. The results of experiment in vitro showed that AS III promoted NSCLC apoptosis by down-regulating the phosphorylation levels of P38, JNK, and AKT (p < 0.01), inhibiting the expression of Bcl-2 (p < 0.01), and up-regulating the expression of Bax (p < 0.01).

Conclusion

These findings provide a mechanism whereby AS III treatment induces apoptosis in NSCLC cells, which may be achieved in part via modulation of the P38, ERK and mTOR signaling pathways.
Appendix
Available only for authorised users
Literature
1.
Peng LH, Liao B, Zhu W, Li ZJ, Li KQ. Predicting Drug-Target interactions with Multi-information Fusion. Ieee J Biomedical Health Inf. 2017;21(2):561–72.CrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018). Ca-a Cancer Journal for Clinicians. 2020;70(4):313.CrossRef
3.
Kureshi N, Abidi SSR, Blouin C. A predictive model for Personalized Therapeutic interventions in Non-small Cell Lung Cancer. Ieee J Biomedical Health Inf. 2016;20(1):424–31.CrossRef
4.
Wu J, Tan YL, Chen ZG, Zhao M. Decision based on big data research for non-small cell Lung cancer in medical artificial system in developing country. Comput Methods Programs Biomed. 2018;159:87–101.PubMedCrossRef
5.
Ding P, Yin R, Luo J, Kwoh C-K. Ensemble prediction of synergistic drug combinations incorporating Biological, Chemical, Pharmacological, and Network Knowledge. Ieee J Biomedical Health Inf. 2019;23(3):1336–45.CrossRef
6.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69(1):7–34.CrossRef
7.
8.
Neal RD, Hamilton W, Rogers TK. Lung cancer. Bmj-British Med J. 2014;349.
9.
Sheng J, Li F, Wong STC. Optimal drug Prediction from Personal Genomics profiles. Ieee J Biomedical Health Inf. 2015;19(4):1264–70.CrossRef
10.
Amitava D. In: Jeffrey KA, Keri CS, editors. Chapter 4 - antiinflammatory herbal supplements. Translational Inflammation: Academic Press; 2019. pp. 69–91.
11.
Dasgupta A. In: Actor JK, Smith KC, editors. Chapter 4 - antiinflammatory herbal supplements. Translational Inflammation: Academic Press; 2019. pp. 69–91.
12.
Lahans T. Chapter 3 - Colorectal Cancer. In: Lahans T, editor. Integrating Conventional and Chinese Medicine in Cancer Care. Edinburgh: Churchill Livingstone; 2007. pp. 61–88.CrossRef
13.
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV alleviates cerebral ischemia-reperfusion Injury through NLRP3 inflammasome-mediated pyroptosis inhibition via activating Nrf2. Oxid Med Cell Longev. 2021;2021:9925561.PubMedPubMedCentralCrossRef
14.
Wang Y, Auyeung KK, Zhang X, Ko JK. Astragalus saponins modulates colon Cancer development by regulating calpain-mediated glucose-regulated protein expression. BMC Complement Altern Med. 2014;14(1):401.PubMedPubMedCentralCrossRef
15.
Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus Membranaceus inhibit Breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 2018;18(1):83.PubMedPubMedCentralCrossRef
16.
Zhang J, Qiao Y, Li D, Hao S, Zhang F, Zhang X, et al. Aqueous extract from Astragalus Membranaceus can improve the function degradation and Delay Aging on Drosophila melanogaster through antioxidant mechanism. Rejuven Res. 2022;25(4):181–90.CrossRef
17.
Auyeung KK, Law PC, Ko JK. Astragalus saponins induce apoptosis via an ERK-independent NF-kappaB signaling pathway in the human hepatocellular HepG2 cell line. Int J Mol Med. 2009;23(2):189–96.PubMed
18.
Tin MM, Cho CH, Chan K, James AE, Ko JK. Astragalus saponins induce growth inhibition and apoptosis in human colon Cancer cells and Tumor xenograft. Carcinogenesis. 2007;28(6):1347–55.PubMedCrossRef
19.
Auyeung KK, Woo PK, Law PC, Ko JK. Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol. 2012;141(2):635–41.PubMedCrossRef
20.
21.
Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, et al. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic Metastasis in Lung cancer patients. J Exp Clin Cancer Res. 2012;31(1):70.PubMedPubMedCentralCrossRef
22.
Lin Y, Lin G, Fang W, Zhu H, Chu K. Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype. Med Oncol. 2014;31(12):327.PubMedCrossRef
23.
Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, et al. Overexpression of annexin 1 in Pancreatic cancer and its clinical significance. World J Gastroenterol. 2004;10(10):1466–70.PubMedPubMedCentralCrossRef
24.
Li CF, Shen KH, Huang LC, Huang HY, Wang YH, Wu TF. Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma. Pathology. 2010;42(1):43–9.PubMedCrossRef
25.
Rodrigo JP, Garcia-Pedrero JM, Fernandez MP, Morgan RO, Suárez C, Herrero A. Annexin A1 expression in nasopharyngeal carcinoma correlates with squamous differentiation. Am J Rhinol. 2005;19(5):483–7.PubMedCrossRef
26.
Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res. 2000;60(22):6293–7.PubMed
27.
Jia L, Lv D, Zhang S, Wang Z, Zhou B. Astragaloside IV inhibits the progression of Non-small Cell Lung Cancer through the Akt/GSK-3β/β-Catenin pathway. Oncol Res. 2019;27(4):503–8.PubMedPubMedCentralCrossRef
28.
Lai ST, Wang Y, Peng F. Astragaloside IV sensitizes non-small cell Lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy. J Thorac Dis. 2020;12(7):3715–24.PubMedPubMedCentralCrossRef
29.
Sabran A, Kumolosasi E, Jantan I. Effects of annexin A1 on apoptosis and cell cycle arrest in human leukemic cell lines. Acta Pharm. 2019;69(1):75–86.PubMedCrossRef
30.
Sairanen T, Szepesi R, Karjalainen-Lindsberg ML, Saksi J, Paetau A, Lindsberg PJ. Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human Stroke. Acta Neuropathol. 2009;118(4):541–52.PubMedCrossRef
31.
32.
Lamark T, Svenning S, Johansen T. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays Biochem. 2017;61(6):609–24.PubMedCrossRef
33.
Kamenz J, Ferrell JE. Jr. The temporal ordering of cell-cycle phosphorylation. Mol Cell. 2017;65(3):371–3.PubMedCrossRef
34.
Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8–17.PubMedCrossRef
35.
Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7–33.
36.
37.
38.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–d92.PubMedCrossRef
39.
Fu Z, Zhang S, Wang B, Huang W, Zheng L, Cheng A. Annexin A1: a double-edged sword as novel cancer biomarker. Clin Chim Acta. 2020;504:36–42.PubMedCrossRef
40.
41.
Li G, He S, Chang L, Lu H, Zhang H, Zhang H, et al. GADD45 alpha and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine. 2011;18(8–9):704–9.PubMedCrossRef
42.
43.
Beroske L, Van den Wyngaert T, Stroobants S, Van der Veken P, Elvas F. Molecular imaging of apoptosis: the case of Caspase-3 Radiotracers. Int J Mol Sci. 2021;22(8).
44.
Koh DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res. 2005;52(1):5–14.PubMedCrossRef
45.
Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res. 2002;45(2):73–85.PubMedCrossRef
46.
Aggarwal BB, Bhardwaj U, Takada Y, REGULATION OF TRAIL-INDUCED APOPTOSIS BY ECTOPIC, EXPRESSION OF ANTIAPOPTOTIC FACTORS. In: Litwack G, editor. Trail. Vitamins and Hormones. 672004. p. 453 – 83.
47.
Silva FFVE, Elena Padin-Iruegas M, Alberto Caponio VC, Lorenzo-Pouso AI, Saavedra-Nieves P, Micaela Chamorro-Petronacci C et al. Caspase 3 and Cleaved Caspase 3 Expression in Tumorogenesis and Its Correlations with Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2022;23(19).
48.
Bianchi AR, De Maio A. Synthesis and degradation of poly(ADP-ribose) in plants. Front Bioscience-Landmark. 2014;19:1436–44.CrossRef
49.
Kirby IT, Cohen MS. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics. In: Cravatt BF, Hsu KL, Weerapana E, editors. Activity-Based Protein Profiling. Current Topics in Microbiology and Immunology. 4202019. p. 211 – 31.
50.
Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of Ovarian cancer. Womens Health. 2018;14.
51.
Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science. 1990;249(4964):64–7.PubMedCrossRef
52.
53.
Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death & Differentiation. 2009;16(3):368–77.CrossRef
54.
Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001;2(3):222–8.PubMedPubMedCentralCrossRef
55.
56.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49.PubMedCrossRef
57.
Ventura JJ, Hübner A, Zhang C, Flavell RA, Shokat KM, Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell. 2006;21(5):701–10.PubMedCrossRef
58.
Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell & Bioscience. 2020;10(1):31.CrossRef
59.
Boyle KB, Randow F. The role of ‘eat-me’ signals and autophagy cargo receptors in innate immunity. Curr Opin Microbiol. 2013;16(3):339–48.PubMedCrossRef
60.
Gao W, Chen Z, Wang W, Stang MT. E1-like activating enzyme Atg7 is preferentially sequestered into p62 aggregates via its interaction with LC3-I. PLoS ONE. 2013;8(9):e73229.PubMedPubMedCentralCrossRef
Metadata
Title
Proteomic analysis reveals the molecular mechanism of Astragaloside in the treatment of non-small cell lung cancer by inducing apoptosis
Authors
Jiaqi Liu
Yan Sun
Wenjing Chen
Lingling Deng
Mengmeng Chen
Jingcheng Dong
Publication date
01-12-2023
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04305-0

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Retraction Note

Retraction Note: Protocatechuic aldehyde from Salvia miltiorrhiza exhibits an anti-inflammatory effect through inhibiting MAPK signalling pathway

Research

Correlation between secondary metabolites of Iris confusa Sealy and Iris pseudacorus L. and their newly explored antiprotozoal potentials

Research

Preliminary in vitro cytotoxic evaluation of Uncaria gambier (Hunt) Roxb extract as a potential herbal-based pulpotomy medicament

Research

Effects of laughter yoga on health-related quality of life in cancer patients undergoing chemotherapy: a randomized clinical trial

Research

Allopathic Medicine Practitioners’ perspectives on facilitating disclosure of traditional medicine use in Gauteng, South Africa: a qualitative study

Retraction Note

Retraction Note: Suppression of NF-κB signaling by ECN in an arthritic model of inflammation